{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 104 of 128', '11. Ruzicka T, Lynde CW, Jemec GBE, Diepgen T, Berth-Jones J, Coenraads PJ, et al.', 'Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic', 'hand eczema refractory to topical corticosteroids: results of a randomized, double-blind,', 'placebo-controlled, multicentre trial. British Journal of Dermatology. 2008;158:808-817.', '12. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement:', 'updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.', '13. Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a', 'scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver', 'reliability. Br J Dermatol. 2005 Feb; 152(2):302-7.', '14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical', 'measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.', '15. Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single', 'European currency for EQ-5D health states. Results from a six-country study. Eur J Health', 'Econ. 2003;4(3):222-231.', '16. Oosterhaven JAF, Schuttelaar MLA, Apfelbacher C, Diepgen TL, Ofenloch RF. Guideline', 'for translation and national validation of the Quality of Life in Hand Eczema', 'Questionnaire (QOLHEQ). Contact Dermatitis. 017;77:106-115.', '17. Ofenloch RF, Oosterhaven JAF, Susitaival P, et al. Cross-cultural validation of the Quality', 'of Life in Hand Eczema Questionnaire (QOLHEQ). J Invest Dermatol. 017;137:1454-', '1460.', '18. Ofenloch R F, Weisshaar E, Dumke AK et al. The Quality of Life in Hand Eczema', 'Questionnaire (QOLHEQ): validation of the German version of a new disease-specific', 'measure of quality of life for patients with hand eczema. Br J Dermatol 2014;171: 304-', '312.', '19. Ofenloch R, Susitaivel P, Svensson A et al. First results from the development of a new', 'disease-specific quality of life instrument. 6th International Dermato-Epidemiology', 'Association Congress. Br J Dermatol 2012;167:e1-25.', '20. Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work', 'Limitations Questionnaire. Med Care. 2001;39:72-85.', '21. FDA. Attachment to discussion document for patient-focused drug development public', 'workshop on Guidance 3: Select, develop or modify fit-for-purpose clinical outcome', 'assessments, Appendices. 2018.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 105 of 128', '22. European Parliament and Council of The European Union. Directive 2001/20/EC of 4', 'April 2001 on the approximation of the laws, regulations and administrative provisions of', 'the Member States relating to the implementation of good clinical practice in the conduct', 'of clinical trials on medicinal products for human use [2001], article 10.', '23. EMA. \"Qualification Opinion of MCP-Mod as an efficient statistical methodology for', 'model-based design and analysis of Phase II dosefinding studies undermodel uncertainty\"', '(2014).', 'http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_gu', 'ideline/2014/02/WC500161027.pdf', '24. Bretz F, Pinheiro JC, Branson M. Combining Multiple Comparisons and Modeling', 'Techniques in Dose-Response Studies. Biometrics. 2005;61:738-748', '25. Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a', 'Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic', 'dermatitis: a phase II, multicentre randomized, vehicle-controlled clinical study. Br J', 'Dermatol. 2018;178:424-432.', '26. World Medical Association 2013. Declaration of Helsinki - ethical principles for medical', 'research involving human subjects. 7th (Fortaleza) amendment.', '27. International Ethical Guidelines for Health-related Research Involving Humans, Fourth', 'Edition. Geneva. Council for International Organizations of Medical Sciences (CIOMS);', '2016.', '28. International Council for Harmonisation of Technical Requirements for Pharmaceuticals', 'for Human Use (ICH) 2016. Integrated addendum to ICH E6(R1): Guideline for good', 'clinical practice E6(R2).']\n\n###\n\n", "completion": "END"}